Granted Patent
B2
US 12,253,515 · App. 16/762,227 · Granted Mar 18, 2025
Method for inhibiting the expression of cancer-promoting factors
Assignees:
National University Corporation Tokyo Medical and Dental University; Nippon Zoki Pharmaceutical Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided are an expression inhibitor of a cancer promoting factor based on the discovery of a new factor influencing the expression amount/level of a cancer promoting factor, and a development tool therefor. Provided are also a diagnostic agent and a diagnosis method for cancer. More specifically provided are: an expression inhibitor of a cancer promoting factor containing at least one kind of inhibitor selected from the group consisting of RBMS expression inhibitor and RBMS function inhibitor; a screening method using as an indicator the expression or the function of RBMS; an expression cassette useful for the method; as well as a diagnostic agent containing a product detection agent for RBMS gene expression and cancer detection method using as an indicator RBMS gene expression amount/level.
Claims (7)
1. A method for inhibiting the expression of at least one cancer promoting factor comprising administering at least one RNA-binding motif, single-stranded-interacting protein 2 (RBMS2) expression inhibitor to a patient having at least one type of cancer in need of inhibition of the expression of at least one cancer promoting factor, wherein the at least one RBMS2 expression inhibitor is selected from the group consisting of a RBMS2-specific siRNA, a miRNA inhibiting the translation of a gene encoding RBMS2, a RBMS2-specific antisense nucleic acid, and expression vectors thereof.
2. The method according to claim 1 , wherein the at least one cancer promoting factor is selected from the group consisting of CSF2, IL-6, ADAM10, ADM, CTGF, HBEGF, HILPDA, IL-24, THBS1, MYC, TGFB2, ITGA6, F3, PTP4A1, HSPA5, PLAU, CYR61, ITGA6, EDIL3, CSF1, ITGB1 and MMP1.
3. The method according to claim 1 , wherein the at least one type of cancer is:
(X) selected from the group consisting of pancreatic cancer, colorectal cancer, lung cancer, bile duct cancer and breast cancer;
(Y) a cancer of a type of RAS gene mutation; and/or
(Z) a highly malignant cancer.
4. The method according to claim 3 , wherein the RAS gene mutation is a KRAS gene mutation.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 7, 2020
From: ASAHARA, HIROSHI; CHIBA, TOMOKI; ABE, KENTARO
To: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY; NIPPON ZOKI PHARMACEUTICAL CO., LTD.
Reel/Frame 052599/0897 →
Priority Claims (1)
JP 2017-216747
· Nov 9, 2017
· national
Continuity (1)
References Cited (99)
US 20100099746A1
· Yamada et al.
· 2010
[cited by applicant]
US 20110053804A1
· Massague et al.
· 2011
[cited by applicant]
US 20130274128A1
· Reiter
· 2013
[cited by applicant]
US 20160068916A1
· Nekarda et al.
· 2016
[cited by applicant]
US 20190242875A1
· Asahara et al.
· 2019
[cited by applicant]
CA 2455447A1
· 2003
[cited by examiner]
CN 101389957A
· 2009
[cited by applicant]
JP 2009159869A
· 2009
[cited by applicant]
JP 2014518610A
· 2014
[cited by applicant]
JP 2014236717A
· 2014
[cited by applicant]
JP 2015522260A
· 2015
[cited by applicant]
JP 2016512032A
· 2016
[cited by applicant]
WO 2003074654A2
· 2003
[cited by applicant]
WO 2007118149A2
· 2007
[cited by applicant]
WO 2008044787A1
· 2008
[cited by applicant]
WO 2011123388A1
· 2011
[cited by applicant]
WO 2012046063A2
· 2012
[cited by applicant]
WO 2012122499A2
· 2012
[cited by applicant]
WO 2013188846A1
· 2013
[cited by applicant]
WO 2014159791A1
· 2014
[cited by applicant]
WO 2016106404A2
· 2016
[cited by applicant]
WO 2016161361A1
· 2016
[cited by applicant]
WO 2017195809A1
· 2017
[cited by applicant]
Sun et al. (Journal of Experimental & Clinical Cancer Research, 2018, 37:298), plus Supplementary Information.
[cited by examiner]
David Bartel (Cell, 2009, 136:215-233).
[cited by examiner]
Valle Oseguera and Spencer (PLOS One, 2014 vol. 9:e88708, pp. 1-8).
[cited by examiner]
Monti et al. (Cancer Research, 2003 vol. 63:7451-7461).
[cited by examiner]
Flieger et al. (Clin Exp Immunol., 2001 vol. 123: 9-14).
[cited by examiner]
Extended European Search Report issued in EP Patent Application No. 18876883.2, dated Jul. 30, 2021, 11 pages.
[cited by applicant]
Yu et al., “RBMS1 Suppresses Colon Cancer Metastasis through Targeted Stabilization of Its mRNA Regulon,” Cancer Discovery 10(9):1410-1423 (2020).
[cited by applicant]
Chang et al., “The IL-6/JAK/Stat3 Feed-Forward Loop Drives Tumorigenesis and Metastasis,” Neoplasia 15 (7):848-862 (2013).
[cited by applicant]
Elinav et al., “Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms,” Nat Rev Cancer 13(11):759-771 (2013).
[cited by applicant]
Gao et al., “Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas,” J Clin Invest 117(12):3846-3856 (2007).
[cited by applicant]
Grivennikov et al., “Autocrine IL-6 Signaling: A Key Event in Tumorigenesis?” Cancer Cell 13(1):7-9 (2008).
[cited by applicant]
Hartman et al., “Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8,” Cancer Res 73(11):3470-3480 (2013).
[cited by applicant]
He et al., “Identification of Liver Cancer Progenitors Whose Malignant Progression Depends on Autocrine IL-6 Signaling,” Cell 155(2):384-396 (2013).
[cited by applicant]
Jayasena et al., “Rbms3 functions in craniofacial development by posttranscriptionally modulating TGF-βsignaling,” J. Cell Bio. 199(3):453-466 (2012).
[cited by applicant]
Journal of Japan Society of Immunology & Allergology in Otolaryngology, 2016, vol. 34, No. 1, pp. 13-18 (English Abstract).
[cited by applicant]
Kulbe et al., “The Inflammatory Cycokine Tumor Necrosis Factor-α Generates an Autocrine Tumor-Promoting Network In Epithelial Ovarian Cancer Cells,” Cancer Res 67(2):585-592 (2007).
[cited by applicant]
Lecture abstracts of BMB2015, (Collaborative conference of the 38th annual conference of the Molecular Biology Society of Japan and the 88th conference of the Japanese Biochemical Society), 2015, p. 1P0844.
[cited by applicant]
Lee et al., “Identification of Novel Alternatively Spliced Transcripts of RBMS3 in Skeletal Muscle with Correlations to Insulin Action in vivo,” J. Exp. Biomed. Sci. 15:301-307 (2009).
[cited by applicant]
Leppek et al., “An optimized streptavidin-binding RNA aptamer for purification of ribonucleoprotein complexes identifies novel ARE-binding proteins,” Nucleic Acids Research, 42 (2):1-15 (2014).
[cited by applicant]
Penkov et al., “Cloning of a human gene closely related to the genes coding for the c-myc single-strand binding proteins,” Gene 243:27-36 (2000).
[cited by applicant]
Rodriguez-Barrueco et al., “Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers,” Genes Dev 29(15):1631-1648 (2015).
[cited by applicant]
Sansone et al., “IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland,” J Clin Invest 117(12):3988-4002 (2007).
[cited by applicant]
Yeh et al., “Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion,” Oncogene 25(31):4300-4309 (2006).
[cited by applicant]
Zhou et al., “Autocrine HBEGF expression promotes breast cancer intravasation, metastasis and macrophage-independent invasion in vivo,” Oncogene 33(29)3784-3793 (2014).
[cited by applicant]
International Search Report issued in PCT/JP2018/041758, mailed Feb. 12, 2019, 5 pages.
[cited by applicant]
Alten et al., “Tocilizumab: A novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases,” Annals of Medicine 45(4):357-363 (2013).
[cited by applicant]
Asahara et al., “Inflammatory Signal Regulation at RNA Level”, BMB2015 (Joint Meeting of the 38th Annual Meeting of the Molecular Biology Society of Japan and the 88th Annual Meeting of the Japanese Biochemical Society)…
[cited by applicant]
Becher et al., “Cytokine networks in neuroinflammation,” Nature Reviews Immunology 17(1):49-59 (2017).
[cited by applicant]
Benveniste et al., “Involvement of the Janus Kinase/Signal Transducer and Activator of Transcription Signaling Pathway in Multiple Sclerosis and the Animal Model of Experimental Autoimmune Encephalomyelitis,” Journal of…
[cited by applicant]
Calich et al., “Osteoarthritis: can anti-cytokine therapy play a role in treatment?” Clin Rheumatol 29(5):451-455 (2010).
[cited by applicant]
Cavaillon et al., “Cytokine Cascade in Sepsis,” Scand J Infect Dis 35(9):535-544 (2003).
[cited by applicant]
Clarke et al., “Single dose oral etoricoxib for acute postoperative pain in adults (Review),” Cochrane Database of Systemic Reviews, Cochrane Library, CD004309, 36 pages (2014).
[cited by applicant]
Cua et al., “Central Nervous System Expression of IL-10 Inhibits Autoimmune Encephalomyelitis,” Journal of Immunology 166:603-608 (2001).
[cited by applicant]
Eisen, “Manifold beneficial effects of acetyl salicylic acid and nonsteroidal anti-inflammatory drugs on sepsis,” Intensive Care Med 38:1249-1257 (2012).
[cited by applicant]
Filion et al., “Monocyte-derived cytokines in multiple sclerosis,” Clin. Exp. Immunol. 131:324-334 (2003).
[cited by applicant]
Firestein et al., “Evolving concepts of rheumatoid arthritis,” Nature 423(6937):356-361 (2003).
[cited by applicant]
Galli et al., “The development of allergic inflammation,” Nature, Macmillan Journals LTD 454(7203):445-454 (2008).
[cited by applicant]
Hermouet et al., “Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation,” Mediators of Inflammation, vol. 2015, Article ID 145293, 16 pages.
[cited by applicant]
Hreggvidsdottir et al., “Inflammatory pathways in spondyloarthritis,” Molecular Immunology 57(1):28-37 (2014).
[cited by applicant]
Ito et al., “Development of a Post-transcriptional Regulator Screening System by Using RNA Binding Protein Gene Library”, BMB2015 (Joint Meeting of the 38th Annual Meeting of the Molecular Biology Society of Japan and t…
[cited by applicant]
Jones et al., “Comparison of U2OS and Huh-7 cells for identifying host factors that affect hepatitis C virus RNA replication,” Journal of General Virology, vol. 91, pp. 2238-2248 (2010).
[cited by applicant]
Kalden, “Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases,” Arthritis Research, vol. 4(Suppl 2):S34-S40 (2002).
[cited by applicant]
Kanaoka et al., “SCR: Novel Human Suppressors of cdc2/cdc13 Mutants of Schizosaccharomyces pombe Harbour Motifs for RNA Binding Proteins,” Nucleic Acids Research 22(13):2687-2693 (1994).
[cited by applicant]
Kang et al., “Therapeutic uses of anti-interleukin-6 receptor antibody,” International Immunology 27(1):21-29 (2014).
[cited by applicant]
Katsikis et al., “Immunoregulatory Role of Interleukin 10 in Rheumatoid Arthritis,” J. Exp. Med. 179(5):1517-1527 (1994).
[cited by applicant]
Kwilasz et al, “The therapeutic potential of interleukin-10 in neuroimmune disease,” Neuropharmacology 95:55-69 (2015).
[cited by applicant]
Latifi et al., “Interleukin-10 Controls the Onset of Irreversible Septic Shock,” Infection and Immunity 70(8):4441-4446 (2002).
[cited by applicant]
Maroon et al., “Natural anti-inflammatory agents for pain relief,” Surgical Neurology International 1:80, 10 pages (2010).
[cited by applicant]
Masuda et al., “Arid5a Controls IL-6 mRNA Stability, Which Contributes to Elevation of IL-6 Level In Vivo,” PNAS 110(23):9409-9414, epub doi: 10.1073/pnas.1307419110 (6 pages) (2013).
[cited by applicant]
McInnes et al., “Cytokines in the pathogenesis of rheumatoid arthritis,” Nature Reviews Immunology 7(6):429-442 (2007).
[cited by applicant]
Mendez-Samperio et al., “Regulation of Interleukin-8 by Interleukin-10 and Transforming Growth Factor B in Human Monocytes Infected with Mycobacterium bovis,” Clinical and Diagnostic Laboratory Immunology 9(4):802-807 (…
[cited by applicant]
Nathan et al., “Nonresolving Inflammation,” Cell 140:871-882 (2010).
[cited by applicant]
Nathan, “Points of control in inflammation,” Nature 420(6917):846-852 (2002).
[cited by applicant]
Niki, et al., “MSSP promotes ras/myc cooperative cell transforming activity by binding to c-Myc,” Genes to Cells 5:127-141 (2000).
[cited by applicant]
Rizzi et al., “Spontaneous remission of ‘methotrexate-associated lymphoproliferative disorders’ after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature,” Med Oncol 26(1):1-9…
[cited by applicant]
Sinatra, “Role of COX-2 Inhibitors in the Evolution of Acute Pain Management,” Journal of Pain and Symptom Management, 24(1S):S18-S27 (2002).
[cited by applicant]
Steinhauser et al., “IL-10 is a Major Mediator of Sepsis-Induced Impairment in Lung Antibacterial Host Defense,” Journal of Immunoloy 162(1):392-399 (1999).
[cited by applicant]
Tanaka et al., “Interleukin-6; Pathogenesis and Treatment of Autoimmune Inflammatory Diseases,” Inflammation and Regeneration 33(1):54-65 (2013).
[cited by applicant]
Van De Ven et al., “Causes and prevention of chronic postsurgical pain,” Current Opinion in Critical Care 18 (4):366-371 (2012).
[cited by applicant]
Zhang et al., “Cytokines, Inflammation, and Pain,” International Anesthesiology Clinics, 27-37 (2007).
[cited by applicant]
Zhang, et al., “Low expression of RBMS3 and SFRP1 are associated with poor prognosis in patients with gastric cancer,” Am J Cancer Res 6(11):2679-2689 (2016).
[cited by applicant]
Zhao et al., “Tristetraprolin Regulates Interleukin-6 Expression Through p38 MAPK-Dependent Affinity Changes with mRNA 3′ Untranslated Region,” Journal of Interferon & Cytokine Research 31(8):629-637, 2011.
[cited by applicant]
File History of U.S. Appl. No. 16/913,376, filed Jun. 26, 2020.
[cited by applicant]
File History of U.S. Appl. No. 16/300,442, filed Nov. 9, 2018.
[cited by applicant]
Ivashchenko et al., Binding sites of miR-1273 family on the mRNA of target genes, Bio Med Research International, vol. 2014, Article ID 620530, 11 pages. (Year: 2014).
[cited by applicant]
Wu et al., “Down regulation of RNA binding motif, single-stranded interacting protein 3, along with up regulation of nuclear HIF1A correlates with poor prognosis in patients with gastric cancer,” Oncotarget 8(1):1262-12…
[cited by applicant]
Mannino et al., “The paradoxical role of IL-10 in immunity and cancer,” Cancer Letters 367:103-107 (2015).
[cited by applicant]
Office Action issued in Canadian Application No. 3,082,006, mailed Oct. 28, 2024, 7 pages.
[cited by applicant]
Cited By (1)